The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.
Zebrafish: an emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery
Open accessAbstract
The zebrafish is a well‐established model organism used in developmental biology. In the last decade, this technology has been extended to the generation of high‐value knowledge on safety risks of novel drugs. Indeed, the larval zebrafish appear to combine advantages of whole organism phenotypic assays and those (rapid production of results with minimal resource engagement) of in vitro high‐throughput screening techniques. Thus, if appropriately evaluated, it can offer undeniable advantages in drug discovery for identification of target and off‐target effects. Here, we review some applications of zebrafish to identify potential safety liabilities, particularly before lead/candidate selection. For instance, zebrafish cardiovascular system can be used to reveal decreases in heart rate and atrial–ventricular dissociation, which may signal human ether‐a‐go‐go‐related gene (h ERG) channel blockade. Another main area of interest is the CNS, where zebrafish behavioural assays have been and are further being developed into screening platforms for assessment of locomotor activity, convulsant and proconvulsant liability, cognitive impairment, drug dependence potential and impaired visual and auditory functions. Zebrafish also offer interesting possibilities for evaluating effects on bone density and gastrointestinal function. Furthermore, available knowledge of the renal system in larval zebrafish can allow identification of potential safety issues of drug candidates on this often neglected area in early development platforms. Although additional validation is certainly needed, the zebrafish is emerging as a versatile in vivo animal model to identify off‐target effects that need investigation and further clarification early in the drug discovery process to reduce the current, high degree of attrition in development. British Journal of Pharmacology (2008) 154, 1400–1413; doi:10.1038/bjp.2008.249; published online 16 June 2008
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mizgerd, J. P., Kubo, H., Kutkoski, G. J., Bhagwan, S. D., Scharffetter-Kochanek, K., Beaudet, A. L., & Doerschuk, C. M. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.8.1357 · Cited by 7,306
The zebrafish book : a guide for the laboratory use of zebrafish (Danio rerio)
Westerfield, M. (1995) · Medical Entomology and Zoology · Cited by 6,813
Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients
Pirmohamed, M., James, S., Meakin, S., Green, C., Scott, A. K., Walley, T. J., Farrar, K., Park, B. K., & Breckenridge, A. M. (2004) · BMJ · doi:10.1136/bmj.329.7456.15 · Cited by 3,230
Animal models of human disease: zebrafish swim into view
Lieschke, G. J., & Currie, P. D. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2091 · Cited by 2,167
Zebrafish as a Model Vertebrate for Investigating Chemical Toxicity
Hill, A. J., Teraoka, H., Heideman, W., & Peterson, R. E. (2005) · Toxicological Sciences · doi:10.1093/toxsci/kfi110 · Cited by 1,374
In vivo drug discovery in the zebrafish
Zon, L. I., & Peterson, R. T. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1606 · Cited by 1,353
A genetic screen for mutations affecting embryogenesis in zebrafish
Driever, W., Solnica-Krezel, L., Schier, A. F., Neuhauss, S. C. F., Malicki, J., Stemple, D. L., Stainier, D. Y. R., Zwartkruis, F., Abdelilah, S., Rangini, Z., et al. (1996) · Development · doi:10.1242/dev.123.1.37 · Cited by 1,337
Koch, M. (1999) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00098-7 · Cited by 1,287 · cited 2×
“simple neuronal circuitry (Koch, 1999).”
BackgroundProduction of clones of homozygous diploid zebra fish (Brachydanio rerio)
Streisinger, G., Walker, C., Dower, N., Knauber, D., & Singer, F. (1981) · Nature · doi:10.1038/291293a0 · Cited by 1,281
Cisplatin Nephrotoxicity: A Review
Yao, X., Panichpisal, K., Kurtzman, N., & Nugent, K. (2007) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31812dfe1e · Cited by 1,251
Cited by
Use of Zebrafish in Drug Discovery Toxicology
Cassar, S., Adatto, I., Freeman, J. L., Gamse, J. T., Iturria, I., Lawrence, C., Muriana, A., Peterson, R. T., Van Cruchten, S., & Zon, L. I. (2020) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00335 · Cited by 561
Diet-induced obesity in zebrafish shares common pathophysiological pathways with mammalian obesity
Oka, T., Nishimura, Y., Zang, L., Hirano, M., Shimada, Y., Wang, Z., Umemoto, N., Kuroyanagi, J., Nishimura, N., & Tanaka, T. (2010) · BMC Physiology · doi:10.1186/1472-6793-10-21 · Cited by 386
Light-Induced Protein Degradation with Photocaged PROTACs
Xue, G., Wang, K., Zhou, D., Zhong, H., & Pan, Z. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b06422 · Cited by 377
Zebrafish embryos and larvae: A new generation of disease models and drug screens
Ali, S., Champagne, D. L., Spaink, H. P., & Richardson, M. K. (2011) · Birth Defects Research Part C: Embryo Today: Reviews · doi:10.1002/bdrc.20206 · Cited by 257
Effect of Various Antiepileptic Drugs in Zebrafish PTZ-Seizure Model.
(2014) · Europe PMC (PubMed Central) · Cited by 46
Metadata
- Authors
- Barros, T. P., Alderton, W. K., Reynolds, H. M., Roach, A. G., & Berghmans, S.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2008-08
- Volume
- 154
- Issue
- 7
- Pages
- 1400-1413
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2006424018
- Cited by
- 275
- References
- 114
- FWCI
- 7.49
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Zebrafish: an emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery. https://app.cochat.ai/papers/10.1038/bjp.2008.249
- The paper
- Barros, T. P., Alderton, W. K., Reynolds, H. M., Roach, A. G., & Berghmans, S. (2008). Zebrafish: an emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery. British Journal of Pharmacology. https://doi.org/10.1038/bjp.2008.249
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.